8-K: Arrowhead Sues Ionis Over Plozasiran Patent Dispute

Arrowhead Pharmaceuticals has filed a lawsuit against Ionis Pharmaceuticals to protect its investigational drug plozasiran from patent infringement claims.

Summary

• Arrowhead Pharmaceuticals (ARWR) initiated a lawsuit against Ionis Pharmaceuticals (IONS) in the U.S. District Court for the District of Delaware on September 10, 2025.
• The lawsuit seeks a declaratory judgment that Ionis's U.S. Patent No. 9,593,333 (the '333 patent') is invalid and/or not infringed by Arrowhead's plozasiran.
• Ionis had previously threatened legal action, alleging Arrowhead unlawfully promoted plozasiran and infringed on the '333 patent.
• Plozasiran, an investigational RNAi therapeutic, is designed to reduce apolipoprotein C-III (APOC3) production and is currently under FDA review with a PDUFA action date of November 18, 2025.
• The PALISADE Phase 3 clinical trial for plozasiran in patients with persistent chylomicronemia (including Familial Chylomicronemia Syndrome, FCS) demonstrated significant efficacy.
• At 10 months, plozasiran reduced median fasting triglyceride levels by 80% (25mg dose) and 78% (50mg dose), compared to a 17% reduction in the placebo group.
• Apolipoprotein C-III levels were reduced by 93% (25mg dose) and 96% (50mg dose) at 10 months.
• Plozasiran treatment led to a significantly lower incidence of acute pancreatitis (4% in plozasiran groups vs. 20% in placebo; odds ratio 0.17, P=0.03).
• The drug has received FDA Breakthrough Therapy, Orphan Drug, and Fast Track Designations, as well as Orphan Medicinal Product Designation from the EMA.
• Arrowhead argues the '333 patent is invalid due to prior art, lack of written description, and enablement, and that plozasiran's RNAi mechanism does not infringe Ionis's ASO technology.
• Arrowhead is not seeking monetary relief but a declaration of non-infringement and invalidity of the patent.

Sentiment

Score: 7

Explanation: The clinical trial results for plozasiran are highly positive, demonstrating significant efficacy in reducing triglycerides and pancreatitis risk, which is a strong indicator for market success. However, the initiation of patent litigation introduces considerable uncertainty and potential delays, tempering the overall sentiment from 'strong buy' to 'buy' or 'hold' until the legal situation clarifies.

Positives

• Plozasiran demonstrated strong efficacy in Phase 3 trials, reducing median fasting triglycerides by up to 80% and ApoC-III levels by up to 96%.
• The incidence of acute pancreatitis was significantly lower in plozasiran-treated patients (4%) compared to placebo (20%).
• Plozasiran has received multiple expedited regulatory designations (Breakthrough Therapy, Orphan Drug, Fast Track) from the FDA and EMA, highlighting its potential.
• The treatment was generally well tolerated, with adverse events similar to placebo, and no observed thrombocytopenia, a key issue with a competitor's drug.
• Arrowhead's CEO emphasized putting patient needs first and vigorously defending against efforts to limit drug availability.
• The drug's effect on triglyceride lowering was consistent regardless of genetic confirmation of FCS, suggesting broad applicability.

Negatives

• The lawsuit introduces significant legal and commercial uncertainty for plozasiran's planned commercialization.
• Ionis Pharmaceuticals has accused Arrowhead of unlawful promotion and making false/misleading comparative statements about plozasiran, which could lead to regulatory scrutiny.
• Some patients in the plozasiran groups experienced increased glycated hemoglobin levels, particularly those with prediabetes or diabetes, which may require management.
• Minor transient increases in ALT and AST levels were observed with plozasiran, though they did not lead to dose interruptions.
• The trial's blinded follow-up was limited to one year, and the sample size was relatively small for a rare condition.

Risks

• The ongoing patent litigation with Ionis Pharmaceuticals poses a risk to plozasiran's commercialization, potentially delaying market entry or requiring licensing agreements.
• Claims of unlawful promotion and misleading comparisons by Ionis could lead to regulatory actions or reputational damage for Arrowhead.
• The '333 patent's broad claims, covering 'any form of an ApoCIII specific inhibitor, any animal, and any therapeutically effective amount,' could be a challenge for Arrowhead to overcome.
• Hyperglycemia observed in some patients with prediabetes or diabetes could be a safety concern, requiring careful monitoring and potentially additional medication.
• The mechanism of hyperglycemia with plozasiran is unclear but may relate to enhanced hydrolysis of triglyceride-rich lipoproteins, increasing hepatic gluconeogenesis.
• The trial primarily studied White patients, so further investigation involving patients of other races is warranted to assess broader applicability and safety.

Future Outlook

Arrowhead expects to receive a decision on its New Drug Application for plozasiran on or before the PDUFA date of November 18, 2025. The company intends to vigorously pursue its claims in the patent litigation against Ionis Pharmaceuticals and is confident it will prove the '333 patent is invalid and not infringed. They also plan to continue evaluating plozasiran in ongoing SHASTA studies for severe hypertriglyceridemia and MUIR studies for mixed hyperlipidemia, and in a linked open-label extension study for FCS.

Management Comments

• "It is unfortunate and troubling that Ionis Pharmaceuticals is attempting to take action that clearly puts their corporate goals ahead of the needs of patients with familial chylomicronemia (FCS), a severe and rare disease characterized by extremely high triglyceride levels which can lead to acute and potentially fatal pancreatitis, chronic abdominal pain, diabetes, hepatic steatosis, and cognitive issues."
• "Arrowhead will not tolerate efforts by Ionis to limit the availability of a potentially important new medicine to members of the FCS community."
• "Arrowhead has been an innovator in RNAi therapeutics for decades and has made countless important discoveries leading to the development of plozasiran and the proprietary TRiMTM platform."
• "Arrowhead has multiple issued US patents that cover plozasiran for the treatment of patients with FCS based entirely on work developed internally at Arrowhead, which Ionis was not involved with and provided no contribution to whatsoever."

Industry Context

This filing highlights the intense competition and patent disputes common in the biopharmaceutical industry, particularly for rare diseases with high unmet needs. The dispute between Arrowhead's RNAi technology and Ionis's ASO technology for ApoCIII inhibition reflects different therapeutic approaches to managing hypertriglyceridemia and FCS. The market for FCS is small but critical, and successful therapies can command significant value. The outcome of this litigation could set precedents for patent enforceability in the rapidly evolving RNA-based therapeutic space.

Comparison to Industry Standards

• Plozasiran's median triglyceride reduction of up to 80% and significant reduction in acute pancreatitis incidence appear superior to standard triglyceride-lowering medications (statins, fibrates, fish oils) which provide minimal benefit for FCS patients and have not been shown to lower pancreatitis risk.
• Compared to Ionis's FDA-approved Tryngolza (olezarsen), plozasiran's Phase 3 results show comparable or potentially superior efficacy in triglyceride reduction and pancreatitis risk, with a different safety profile (e.g., no thrombocytopenia observed with plozasiran, which was a key issue for another ASO, volanesorsen).
• The filing explicitly mentions Ionis's drug Tryngolza (olezarsen) which was approved in December 2024 for adults with FCS, requiring monthly injections and associated with side effects like low platelet counts and elevated liver enzymes. Plozasiran's quarterly dosing and lack of thrombocytopenia are notable differentiators.
• The PALISADE study's findings are consistent with reports of plozasiran's effects in severe hypertriglyceridemia and mixed hyperlipidemia, suggesting broad utility beyond FCS.
• The observed hyperglycemia with plozasiran in some patients with prediabetes or diabetes is a known effect also reported in previous trials of plozasiran and with volanesorsen, suggesting a class effect for ApoC3 inhibitors related to lipid metabolism.

Legal Proceedings

• Arrowhead Pharmaceuticals, Inc. filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc.
• The lawsuit seeks to declare U.S. Patent No. 9,593,333 (the '333 patent) invalid and/or not infringed by Arrowhead's planned commercialization of investigational plozasiran.
• Ionis had previously sent letters accusing Arrowhead of unlawful promotion, false/misleading comparative statements, and patent infringement.
• Arrowhead argues the '333 patent is invalid under 35 U.S.C. §§ 101, 102, 103, and 112 (anticipation, obviousness, written description, enablement).
• Arrowhead also asserts non-infringement, stating plozasiran's RNAi mechanism differs from Ionis's ASO technology and that its pre-approval activities fall under the 'safe harbor' provision (35 U.S.C. § 271(e)(1)).
• Arrowhead is seeking a judicial declaration of invalidity and non-infringement, and an injunction against Ionis from pursuing further infringement charges.

Stakeholder Impact

• **Shareholders:** Potential for significant upside if plozasiran is approved and the patent dispute is resolved favorably, but also risk from litigation costs and potential delays or adverse outcomes.
• **Patients with FCS/Persistent Chylomicronemia:** Positive impact from a potentially highly effective new treatment option that significantly reduces triglycerides and pancreatitis risk, offering an alternative to existing therapies.
• **Employees:** Continued employment and potential growth opportunities if plozasiran is successfully commercialized; increased workload for legal and R&D teams due to litigation.
• **Competitors (Ionis Pharmaceuticals):** Direct competitive threat to their FDA-approved drug Tryngolza; potential for significant legal costs and impact on their patent portfolio if Arrowhead prevails.
• **Regulatory Bodies (FDA, EMA):** Continued review of plozasiran's NDA; potential involvement in addressing claims of unlawful promotion.

Next Steps

• Arrowhead will vigorously pursue its claims in the U.S. District Court for the District of Delaware to declare Ionis's '333 patent invalid and/or not infringed.
• Arrowhead expects an FDA decision on its New Drug Application for plozasiran on or before November 18, 2025.
• Continue ongoing SHASTA studies for severe hypertriglyceridemia (sHTG).
• Continue ongoing MUIR studies for mixed hyperlipidemia.
• Continue a linked open-label extension study for FCS patients from the PALISADE trial.
• Further characterize the genetic spectrum of the trial population and its effect on plozasiran response.

Key Dates

Recommendation

The clinical data for plozasiran is exceptionally strong, demonstrating significant reductions in triglycerides and acute pancreatitis incidence, which would typically warrant a 'strong buy' recommendation given the unmet medical need in FCS. However, the initiation of a patent infringement lawsuit by Ionis Pharmaceuticals introduces substantial legal and commercial uncertainty. While Arrowhead expresses confidence, patent litigation is inherently unpredictable, costly, and can significantly delay market entry or impact profitability through licensing fees. Therefore, a 'hold' recommendation is prudent until there is more clarity on the legal outcome, allowing investors to assess the risk-adjusted value of plozasiran.

Keywords

Plozasiran, RNAi therapeutic, Familial Chylomicronemia Syndrome, FCS, Hypertriglyceridemia, APOC3 inhibitor, Patent litigation, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Drug development, Clinical trials, Lipid-lowering, Pancreatitis, Breakthrough Therapy Designation